Home » Sanofi, Regeneron Report Alirocumab Met Primary Endpoint in Phase III Odyssey Mono
Sanofi, Regeneron Report Alirocumab Met Primary Endpoint in Phase III Odyssey Mono
Sanofi and Regeneron are satisfied with a Phase III trial of alirocumab that met its primary endpoint of reducing levels of the “bad” LDL cholesterol.
Street Insider
Street Insider
Upcoming Events
-
07May
-
14May
-
30May